Gene Writing Platform
Total Trials
14
As Lead Sponsor
1
As Collaborator
13
Total Enrollment
5,813
NCT00007657
Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation
Phase: Phase 3
Role: Collaborator
Start: Dec 31, 1998
Completion: Jun 30, 2006
NCT00582075
Phase II Study of Gamma Knife Radiosurgery and Temozolomide for Brain Metastases
Phase: Phase 2
Start: Jul 31, 2002
Completion: Jun 30, 2015
NCT00070707
Nasonex Compared With Placebo in Participants With Seasonal Allergic Rhinitis (SAR) and Concomitant Asthma (P03280)
Phase: Phase 4
Start: Apr 3, 2003
Completion: Nov 26, 2003
NCT00302081
Three Regimens of PegIntron Plus Ribavirin in Previously Untreated Chronic Hepatitis C, Genotype 2 or 3 (Study P03548)
Start: Aug 31, 2003
Completion: Apr 30, 2008
NCT00441584
The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)
Start: Jul 31, 2005
Completion: Jun 30, 2008
NCT00139932
Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)
Start: Sep 1, 2005
Completion: Nov 21, 2006
NCT00394589
Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)
Start: Mar 31, 2006
Completion: Oct 31, 2008
NCT00358527
Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED)
Start: May 31, 2006
Completion: Nov 30, 2006
NCT00367237
Remicade Study in Psoriatic Arthritis Patients Of Methotrexate-Naïve Disease (RESPOND) (Study P04422)
Completion: Mar 31, 2008
NCT00381017
Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)
Start: Sep 30, 2006
Completion: Not specified
NCT01108549
Treatment of Chronic Fatigue Syndrome and Fibromyalgia With D-ribose- a Multicenter Study
Phase: N/A
Start: Apr 30, 2009
Completion: Sep 30, 2009
NCT04845217
Peppermint Oil for the Treatment of Interstitial Cystitis / Bladder Pain Syndrome
Phase: Phase 1/2
Start: Sep 15, 2021
Completion: Dec 31, 2023
NCT07095049
Safety, Tolerability, and Systemic Exposure of Apo-Si- K170A-C76 in Healthy Volunteers
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 4, 2024
Completion: Aug 30, 2025
Loading map...